Celcuity Inc. (CELC) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumors, led by its pan-PI3K/mTOR inhibitor, gedatolisib. This report covers the quarterly period ended September 30, 2024. The company has not generated any revenue to date and remains in a pre-commercial development phase.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(29.8) million | $(18.4) million | $(75.1) million | $(44.9) million |
| Net Loss Per Share | $(0.70) | $(0.83) | $(1.96) | $(2.05) |
| Operating Expenses | $30.1 million | $18.9 million | $76.8 million | $46.5 million |
| Cash & Cash Equivalents | $12.6 million (as of Sept 30, 2024) | |||
| Short-Term Investments | ||||
| Total Liquidity | $264.1 million | |||
| Long-Term Debt (Net) | $96.9 million | |||
| Accumulated Deficit | $(235.2) million |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 59% in Q3 and 65% YTD compared to the prior year periods. Research and Development (R&D) expenses increased by 58% in Q3 and 66% YTD, driven by the ramp-up of the VIKTORIA-1 Phase 3 trial, the CELC-G-201 Phase 1b/2 trial, and initiation activities for the VIKTORIA-2 Phase 3 trial.
- Financing Activities: In May 2024, the company completed a follow-on equity offering raising approximately $56.3 million in net proceeds. Concurrently, the company entered into an Amended and Restated Loan Agreement, funding the first $100 million tranche (including $61.7 million in new borrowings).
- Debt Structure: Long-term debt increased significantly from $37.0 million at year-end 2023 to $96.9 million at September 30, 2024, reflecting the new loan facility.
- Interest Income: Interest income increased 94% in Q3 and 58% YTD due to higher cash and investment balances resulting from recent financing.
Outlook, Guidance, and Risks
- Clinical Milestones:
- VIKTORIA-1 (Phase 3): Enrollment for the PIK3CA wild-type cohort is 100% complete. Topline data is expected in late Q1 or Q2 2025. PIK3CA mutant cohort data is expected in H2 2025.
- CELC-G-201 (Phase 1b/2): Evaluating gedatolisib with darolutamide for prostate cancer; preliminary data expected in Q2 2025.
- VIKTORIA-2 (Phase 3): First-line breast cancer trial expected to enroll its first patient in Q2 2025.
- Liquidity Outlook: Management believes current cash, investments, and available borrowings under the loan agreement will fund operations through 2026.
- Debt Covenants & Fees: The new loan agreement includes a 4.5% final fee ($4.5 million) and contingent non-utilization fees for future tranches if milestones are met but funds are not drawn. Interest includes a 1.0% payment-in-kind (PIK) component through May 2027.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital if milestones are not met or costs exceed estimates, and the potential dilution from future equity issuances or debt conversion features.
Investor Verification Checklist
- Verify the specific enrollment rates and patient retention metrics for the VIKTORIA-1 trial to assess the likelihood of meeting the Q2 2025 data readout timeline.
- Review the terms of the Amended and Restated Loan Agreement, specifically the financial covenants required to draw the remaining $80 million in committed tranches (Term D and Term E).
- Monitor the burn rate relative to the $264.1 million liquidity position to confirm the "through 2026" runway assumption holds as R&D costs scale for VIKTORIA-2.
- Assess the impact of the 1.0% PIK interest and the $4.5 million final fee on the total cost of capital and future debt principal balance.
- Confirm the status of the Pfizer license agreement and any potential milestone payments or royalty obligations triggered by clinical progress.